Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.
作者信息
Shao Zhimin, Tong Zhongsheng, Liu Qiang, Li Wei, Cai Li, Shen Kunwei, Li Huiping, Wang Chuan, Yang Jin, Song Zhenchuan, Wang Shui, Luo Ting, Zhao Wenhe, Wang Haibo, Pan Yueyin, Nie Jianyun, Zeng Xiaohua, Bai Yanqing, Chiang Wendy, Guarnaccia Valeria, Bi Yu, Xu Binghe
机构信息
Fudan University Shanghai Cancer Center, Shanghai, China.
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
出版信息
Cancer Med. 2024 Aug;13(15):e7408. doi: 10.1002/cam4.7408.
Abstract
摘要
Zotero 插件